Epidemiologic and Survival Trends in Amyloidosis, 1987–2019

This correspondence presents data from over 11,000 cases of amyloidosis diagnosed between 1987 and 2019 using the UK National Amyloidosis Centre database. The findings highlight a 670% increase in diagnoses, improvements in survival, especially among patients with systemic light-chain (AL) amyloidosis, and a notable shift in disease patterns. AA amyloidosis declined due to better control of inflammatory disorders, while awareness and improved imaging techniques led to rising diagnoses of wild-type transthyretin-associated (ATTRwt) amyloidosis. The authors emphasize the role of advanced diagnostics and emerging therapies in transforming care for this historically underdiagnosed and fatal condition.

This correspondence presents data from over 11,000 cases of amyloidosis diagnosed between 1987 and 2019 using the UK National Amyloidosis Centre database. The findings highlight a 670% increase in diagnoses, improvements in survival, especially among patients with systemic light-chain (AL) amyloidosis, and a notable shift in disease patterns. AA amyloidosis declined due to better control of inflammatory disorders, while awareness and improved imaging techniques led to rising diagnoses of wild-type transthyretin-associated (ATTRwt) amyloidosis. The authors emphasize the role of advanced diagnostics and emerging therapies in transforming care for this historically underdiagnosed and fatal condition.